The inflammasome complex known as NLRP3 inflammasome has emerged as a pivotal mediator of innate immune activation, driving the maturation and release of pro-inflammatory cytokines IL-1β and IL-18. Persistent activation of this pathway is implicated in a range of diseases, from inflammatory bowel diseases to neurodegenerative disorders. Fonte
Developed by Roche (via its acquisition of Inflazome), Selnoflast (also known by its developmental codes RO7486967, RG-6418) is an orally active, selective and reversible small-molecule inhibitor of the NLRP3 inflammasome. Preclinical studies demonstrated potent inhibition of IL-1β release in human monocyte-derived macrophages (IC₅₀ in the low nanomolar range), while showing minimal activity on other inflammasomes such as AIM2 and NLRC4. Fonte
In a randomized, double-blind Phase 1b study involving 19 adult patients with moderate to severe active Ulcerative Colitis (UC), Selnoflast at 450 mg once daily for 7 days was well tolerated and achieved plasma trough concentrations above the predicted IL-1β IC₉₀ level. Tissue concentrations in sigmoid colon biopsies exceeded the target threshold as well. However, despite target engagement, no significant differences between treatment and placebo were observed in histological inflammatory markers or stool biomarker profiles. Fonte
Mechanistically, Selnoflast functions by preventing the oligomerization of NLRP3 and the subsequent recruitment of the adaptor protein ASC, thereby blocking caspase-1 activation and the downstream cascade that leads to pyroptosis and cytokine release. This specific mode of action contrasts with broad-spectrum anti-inflammatory drugs, offering the prospect of modulating pathological inflammation without inducing generalized immunosuppression. Fonte
Given the limited therapeutic effect observed in the UC study, the development program has pivoted toward neuro-inflammatory and neurodegenerative conditions. Selnoflast is currently under evaluation in a Phase 1b trial in early Parkinson’s disease, reflecting the strong scientific rationale that NLRP3-mediated inflammation contributes to dopaminergic cell loss, α-synuclein aggregation and progression of neurodegeneration. Fonte
The clinical significance of Selnoflast lies in its potential to constitute a new class of precision immunomodulators targeting innate immune sensors. Should the ongoing trials demonstrate clinical efficacy and safety, Selnoflast may enable therapeutic intervention earlier in the disease course, either alone or in combination with existing symptomatic treatments. Physicians and researchers will pay close attention to the outcome of cardiovascular and neurodegenerative indication trials, especially as biomarkers of inflammasome activation become more validated.
In conclusion, Selnoflast represents a bold step in the evolution of anti-inflammatory therapeutics—from downstream blockade of cytokines to upstream modulation of inflammasome assembly. The future of this molecule will be determined in larger outcome studies, but the concept underscores a broader paradigm shift in immune-targeted therapy.
Copyright © All rights reserved – Salute33